Immune regulation by dendritic cells and T cells - Basic science, diagnostic, and clinical application

Clinical Laboratory

Volumn 57, Issue 1-2, 2011, Pages 1-12

  Tuettenberg, Andrea ^a   Becker, Christian ^a   Correll, Anita ^a   Steinbrink, Kerstin ^a   Jonuleit, Helmut ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Dendritic cells; Immune regulation; Immunological disorders; Immunotherapy; T cells

Indexed keywords

ALLERGY; AUTOIMMUNITY; BONE MARROW CELL; CELL INTERACTION; DENDRITIC CELL; DIAGNOSTIC PROCEDURE; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOTHERAPY; NEOPLASM; PLASTICITY; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY;

BIOLOGICAL MARKER;

BIOLOGICAL MARKERS; DENDRITIC CELLS; HUMANS; IMMUNE TOLERANCE; IMMUNITY; T-LYMPHOCYTES;

EID: 79953810328     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (141)

1. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 1991;9:271-96.
2. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.
3. Jonuleit H, Adema G, Schmitt E. Immune regulation by regulatory T cells: implications for transplantation. Transpl. Immunol. 2003;11:267-76.
4. Jonuleit H, Kuhn U, Muller G, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. 1997;27:3135-42.
5. Jonuleit H, Giesecke-Tuettenberg A, Tuting T, et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int. J. Cancer. 2001;93:243-51.
6. Steinbrink K, Mahnke K, Grabbe S, Enk AH, Jonuleit H. Myeloid dendritic cell: From sentinel of immunity to key player of peripheral tolerance? Hum. Immunol. 2009;70(5):289-93.
7. Mahnke K, Schmitt E, Bonifaz L, Enk AH, Jonuleit H. Immature, but not inactive: the tolerogenic function of immature dendritic cells. Immunol. Cell Biol. 2002;80:477-83.
8. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells [In Process Citation]. Annu Rev Immunol 2000;18: 767-811.
9. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J.Exp.Med. 2000;192:1213-22.
10. Jonuleit H, Schmitt E, Steinbrink K, Enk AH. Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol. 2001;22:394-400. (Pubitemid 32673646)
11. Hawiger D, Inaba K, Dorsett Y, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 2001;194:769-79.
12. Heufler C, Koch F, Schuler G. Granulocyte/macrophage colonystimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells. J. Exp. Med. 1988;167:700-5.
13. Reis e Sousa, Diebold SD, Edwards AD, Rogers N, Schulz O, Sporri R. Regulation of dendritic cell function by microbial stimuli. Pathol. Biol. (Paris) 2003;51:67-8.
14. Jonuleit H, Knop J, Enk AH. Cytokines and their effects on maturation, differentiation and migration of dendritic cells. Arch. Dermatol. Res. 1996;289:1-8.
15. Lanzavecchia A, Sallusto F. The instructive role of dendritic cells on T cell responses: lineages, plasticity and kinetics. Curr. Opin. Immunol. 2001;13:291-8.
16. Lanzavecchia A, Sallusto F. Regulation of T cell immunity by dendritic cells. Cell 2001;106:263-6. (Pubitemid 32772609)
17. Langenkamp A, Messi M, Lanzavecchia A, Sallusto F. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat. Immunol. 2000;1:311-6.
18. Jonuleit H, Giesecke A, Kandemir A, Paragnik L, Knop J, Enk AH. Induction of tumor peptide-specific cytotoxic T cells under serum-free conditions by mature human dendritic cells. Arch. Dermatol. Res. 2000;292:325-32.
19. Steinman RM, Hawiger D, Liu K, et al. Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann. N.Y. Acad. Sci. 2003;987:15-25.
20. Kabelitz D, Wesch D, Oberg HH. Regulation of regulatory T cells: role of dendritic cells and toll-like receptors. Crit Rev. Immunol. 2006;26:291-306.
21. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific Inhibition of Effector T Cell Function in Humans after Injection of Immature Dendritic Cells. J. Exp. Med. 2001;193:233-8.
22. Dhodapkar MV, Steinman RM. Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans. Blood 2002;100:174-7. (Pubitemid 35177444)
23. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000;101:455-8.
24. Levings MK, Bacchetta R, Schulz U, Roncarolo MG. The role of IL-10 and TGF-beta in the differentiation and effector function of T regulatory cells. Int. Arch. Allergy Immunol. 2002; 129:263-76.
25. Fritzsching B, Oberle N, Pauly E, et al. Naive regulatory T cells: a novel subpopulation defined by resistance toward CD95L-mediated cell death. Blood 2006;108:3371-8.
26. Stassen M, Fondel S, Bopp T, et al. Human CD25+ regulatory T cells: two subsets defined by the integrins alpha 4 beta 7 or alpha 4 beta 1 confer distinct suppressive properties upon CD4+ T helper cells. Eur. J. Immunol. 2004;34:1303-11.
27. Baecher-Allan CM, Hafler DA. The purification and functional analysis of human CD4+CD25high regulatory T cells. Curr. Protoc. Immunol. 2006; Chapter 7:Unit.
28. Hill JA, Feuerer M, Tash K et al. Foxp3 transcription-factor-dependent and -independent regulation of the regulatory T cell transcriptional signature. Immunity. 2007;27:786-800. (Pubitemid 350110546)
29. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299: 1057-61. (Pubitemid 36222930)
30. Roncarolo MG, Bacchetta R, Bordignon C, Narula S, Levings MK. Type 1 T regulatory cells. Immunol. Rev. 2001;182:68-79.
31. Levings MK, Roncarolo MG. T-regulatory 1 cells: a novel subset of CD4 T cells with immunoregulatory properties. J Allergy Clin Immunol 2000;106:S109-S112. (Pubitemid 30482844)
32. Weiner HL. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol. Rev. 2001;182:207-14.
33. Fischer K, Voelkl S, Heymann J, et al. Isolation and characterization of human antigen-specific TCR alpha beta+ CD4(-)CD8-double-negative regulatory T cells. Blood 2005;105:2828-35. (Pubitemid 40446276)
34. Bisikirska B, Colgan J, Luban J, Bluestone JA, Herold KC. TCR Stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J. Clin. Invest 2005;115:2904-13. (Pubitemid 41434418)
35. Wan YY. Multi-tasking of helper T cells. Immunology 2010; 130:166-71.
36. Wan YY, Flavell RA. How diverse-CD4 effector T cells and their functions. J. Mol. Cell Biol. 2009;1:20-36.
37. Pulendran B, Tang H, Manicassamy S. Programming dendritic cells to induce T(H)2 and tolerogenic responses. Nat. Immunol. 2010;11:647-55.
38. Hsieh CS, Heimberger AB, Gold JS, O'Garra A, Murphy KM. Differential regulation of T helper phenotype development by interleukins 4 and 10 in an alpha beta T-cell-receptor transgenic system. Proc. Natl. Acad. Sci. U.S.A. 1992;89:6065-9.
39. Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages [see comments]. Science 1993;260:547-9.
40. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006;24:179-89. (Pubitemid 43214587)
41. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 2005;201:233-40.
42. Staudt V, Bothur E, Klein M, et al. Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells. Immunity. 2010;33:192-202.
43. Dardalhon V, Awasthi A, Kwon H, et al. IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells. Nat. Immunol. 2008;9:1347-55.
44. Veldhoen M. Interferon regulatory factor 4: combinational control of lymphocyte differentiation. Immunity. 2010;33:141-3.
45. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol. Rev. 2006;212:28-50.
46. Tuettenberg A, Huter E, Hubo M, et al. The role of ICOS in directing T cell responses: ICOS-dependent induction of T cell anergy by tolerogenic dendritic cells. J. Immunol. 2009;182: 3349-56.
47. Tuettenberg A, Fondel S, Steinbrink K, Enk AH, Jonuleit H. CD40 signalling induces IL-10-producing, tolerogenic dendritic cells. Exp. Dermatol. 2010;19:44-53.
48. Lohning M, Hutloff A, Kallinich T, et al. Expression of ICOS in vivo defines CD4+ effector T cells with high inflammatory potential and a strong bias for secretion of interleukin 10. J. Exp. Med.2003;20;197:181-93.
49. Grewal IS, Flavell RA. The role of CD40 ligand in costimulation and T-cell activation. Immunol. Rev. 1996;153:85-106.
50. Steinbrink K, Jonuleit H, Muller G, Schuler G, Knop J, Enk AH. Interleukin-10-treated human dendritic cells induce a melanomaantigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood 1999;93:1634-42. (Pubitemid 29102491)
51. Steinbrink K, Graulich E, Kubsch S, Knop J, Enk AH. CD4(+) and CD8(+) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood 2002;99:2468-76. (Pubitemid 34525434)
52. Adler HS, Kubsch S, Graulich E, Ludwig S, Knop J, Steinbrink K. Activation of MAP kinase p38 is critical for the cell-cycle-controlled suppressor function of regulatory T cells. Blood 2007;109:4351-9. (Pubitemid 46743403)
53. Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc. Natl. Acad. Sci. U.S.A 2008;105:10113-8.
54. Cederbom L, Hall H, Ivars F. CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur. J. Immunol. 2000;30:1538-43.
55. Oderup C, Cederbom L, Makowska A, Cilio CM, Ivars F. Cytotoxic T lymphocyte antigen-4-dependent down-modulation of costimulatory molecules on dendritic cells in CD4+ CD25+ regulatory T-cell-mediated suppression. Immunology 2006;118: 240-9. (Pubitemid 43727429)
56. Tadokoro CE, Shakhar G, Shen S, et al. Regulatory T cells inhibit stable contacts between CD4+ T cells and dendritic cells in vivo. J. Exp. Med. 2006;203:505-11.
57. Seyerl M, Kirchberger S, Majdic O, et al. Human rhinoviruses induce IL-35-producing Treg via induction of B7-H1 (CD274) and sialoadhesin (CD169) on DC. Eur. J. Immunol. 2010;40: 321-9.
58. Houot R, Perrot I, Garcia E, Durand I, Lebecque S. Human CD4+CD25high regulatory T cells modulate myeloid but not plasmacytoid dendritic cells activation. J. Immunol. 2006;176: 5293-8.
59. Huang CT, Workman CJ, Flies D, et al. Role of LAG-3 in regulatory T cells. Immunity. 2004;21:503-13.
60. Liang B, Workman C, Lee J, et al. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J. Immunol. 2008;180:5916-26.
61. Sarris M, Andersen KG, Randow F, Mayr L, Betz AG. Neuropilin-1 expression on regulatory T cells enhances their interactions with dendritic cells during antigen recognition. Immunity. 2008; 28:402-13.
62. Mandapathil M, Szczepanski MJ, Szajnik M, et al. Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J. Biol. Chem. 2010;285:27571-80.
63. Mandapathil M, Hilldorfer B, Szczepanski MJ, et al. Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J. Biol. Chem. 2010;285:7176-86.
64. Deaglio S, Dwyer KM, Gao W, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 2007;204:1257-65.
65. Yamazaki S, Inaba K, Tarbell KV, Steinman RM. Dendritic cells expand antigen-specific Foxp3+ CD25+ CD4+ regulatory T cells including suppressors of alloreactivity. Immunol. Rev. 2006;212:314-29.
66. Yamazaki S, Dudziak D, Heidkamp GF, et al. CD8+ CD205+ splenic dendritic cells are specialized to induce Foxp3+ regulatory T cells. J. Immunol. 2008;181:6923-33.
67. Baecher-Allan C, Hafler DA. Human regulatory T cells and their role in autoimmune disease. Immunol.Rev. 2006;212:203-16.
68. Baecher-AIlan C, Anderson DE. Immune regulation in tumor-bearing hosts. Curr. Opin. Immunol. 2006;18:214-9.
69. Sugiyama H, Gyulai R, Toichi E, et al. Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J. Immunol. 2005;174:164-73. (Pubitemid 40007402)
70. Ehrenstein MR, Evans JG, Singh A, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J. Exp. Med. 2004;200:277-85.
71. Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J. Exp. Med. 2007;204:33-9.
72. Ling EM, Smith T, Nguyen XD, et al. Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 2004; 363:608-15. (Pubitemid 38264178)
73. Akdis M, Blaser K, Akdis CA. T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases. J. Allergy Clin. Immunol. 2005;116:961-8.
74. Hawrylowicz CM, O'Garra A. Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. Nat. Rev. Immunol. 2005;5:271-83.
75. Xystrakis E, Kusumakar S, Boswell S, et al. Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. J. Clin. Invest. 2006;116: 146-55.
76. Viguier M, Lemaitre F, Verola O, et al. Foxp3 expressing CD4+ CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J.,Immunol. 2004;173:1444-53. (Pubitemid 38924326)
77. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004;10:942-9.
78. Correll A, Tuettenberg A, Becker C, Jonuleit H. Increased regulatory T-cell frequencies in patients with advanced melanoma correlate with a generally impaired T-cell responsiveness and are restored after dendritic cell-based vaccination. Exp. Dermatol. 2010;19:e213-e221.
79. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-64.
80. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25 (+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000;192:295-302. (Pubitemid 30470312)
81. Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat. Immunol. 2003;4:337-42.
82. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 2003;4:330-6.
83. Banham AH, Powrie FM, Suri-Payer E. FOXP3+ regulatory T cells: Current controversies and future perspectives. Eur. J. Immunol. 2006;36:2832-6.
84. Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J. Exp. Med. 2006;203:1701-11.
85. Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat. Med. 2003;9:1144-50.
86. Ziegler SF. FOXP3: not just for regulatory T cells anymore. Eur. J. Immunol. 2007;37:21-3.
87. Simonetta F, Chiali A, Cordier C, et al. Increased CD127 expression on activated FOXP3+CD4+ regulatory T cells. Eur. J. Immunol. 2010;40:2528-38.
88. Tran DQ, Andersson J, Wang R, Ramsey H, Unutmaz D, Shevach EM. GARP (LRRC32) is essential for the surface expression of latent TGF-beta on platelets and activated FOXP3+ regulatory T cells. Proc. Natl. Acad. Sci.U.S.A 2009;106:13445-50.
89. Wang R, Kozhaya L, Mercer F, Khaitan A, Fujii H, Unutmaz D. Expression of GARP selectively identifies activated human FOXP3+ regulatory T cells. Proc. Natl. Acad. Sci.U.S.A 2009; 106:13439-44.
90. Borsellino G, Kleinewietfeld M, Di MD, et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007;110: 1225-32. (Pubitemid 47281420)
91. Bonnin B, Correll A, Swiatek-de LM, et al. Large scale preparation of human MHC class II+ integrin beta(1)+ Tregs. J. Immunol. Methods 2010;360:96-102.
92. Getnet D, Grosso JF, Goldberg MV, et al. A role for the transcription factor Helios in human CD4(+)CD25(+) regulatory T cells. Mol. Immunol. 2010;47:1595-600.
93. Thornton AM, Korty PE, Tran DQ, et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J. Immunol. 2010;184:3433-41.
94. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998;188:287-96. (Pubitemid 28357757)
95. Kruse M, Rosorius O, Kratzer F, et al. Inhibition of CD83 cell surface expression during dendritic cell maturation by interference with nuclear export of CD83 mRNA. J Exp Med 2000;191: 1581-90.
96. Soumelis V, Liu YJ. From plasmacytoid to dendritic cell: morphological and functional switches during plasmacytoid pre-dendritic cell differentiation. Eur. J. Immunol. 2006;36:2286-92.
97. Hadeiba H, Sato T, Habtezion A, Oderup C, Pan J, Butcher EC. CCR9 expression defines tolerogenic plasmacytoid dendritic cells able to suppress acute graft-versus-host disease. Nat. Immunol. 2008;9:1253-60.
98. Dzionek A, Fuchs A, Schmidt P, et al. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J. Immunol. 2000;165:6037-46.
99. Swiecki M, Colonna M. Accumulation of plasmacytoid DC: Roles in disease pathogenesis and targets for immunotherapy. Eur. J. Immunol. 2010;40:2094-8.
100. Swiecki M, Colonna M. Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol. Rev. 2010;234:142-62.
101. Jongbloed SL, Kassianos AJ, McDonald KJ, et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J. Exp. Med. 2010;207:1247-60.
102. Poulin LF, Salio M, Griessinger E, et al. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J. Exp. Med. 2010;207: 1261-71.
103. Crozat K, Guiton R, Contreras V, et al. The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells. J. Exp. Med. 2010;207:1283-92.
104. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. Nat. Rev. Immunol. 2010;10:490-500.
105. Miyara M, Wing K, Sakaguchi S. Therapeutic approaches to allergy and autoimmunity based on FoxP3+ regulatory T-cell activation and expansion. J. Allergy Clin. Immunol. 2009;123: 749-55.
106. Hvas CL, Kelsen J, Agnholt J, Dige A, Christensen LA, Dahlerup JF. Discrete changes in circulating regulatory T cells during infliximab treatment of Crohn's disease. Autoimmunity 2010;43: 325-33.
107. Farrell RA, Giovannoni G. Current and future role of interferon beta in the therapy of multiple sclerosis. J. Interferon Cytokine Res. 2010;30:715-26.
108. Becker C, Taube C, Bopp T, et al. Protection from graft-versushost disease by HIV-1 envelope protein gp120-mediated activation of human CD4+CD25+ regulatory T cells. Blood 2009;114: 1263-9.
109. Bopp T, Dehzad N, Reuter S, et al. Inhibition of cAMP degradation improves regulatory T cell-mediated suppression. J. Immunol. 2009;182:4017-24.
110. Becker C, Kubach J, Wijdenes J, Knop J, Jonuleit H. CD4-mediated functional activation of human CD4+CD25+ regulatory T cells. Eur. J. Immunol. 2007;37:1217-23.
111. Bresson D, Togher L, Rodrigo E, et al. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J. Clin. Invest 2006; 116:1371-81.
112. Gorman S, Judge MA, Hart PH. Immune-modifying properties of topical vitamin D: Focus on dendritic cells and T cells. J. Steroid Biochem. Mol. Biol. 2010;121:247-9.
113. Gorman S, Kuritzky LA, Judge MA, et al. Topically applied 1,25-dihydroxyvitamin D3 enhances the suppressive activity of CD4+CD25+ cells in the draining lymph nodes. J. Immunol. 2007;179:6273-83.
114. Ehser S, Chuang JJ, Kleist C, et al. Suppressive dendritic cells as a tool for controlling allograft rejection in organ transplantation: promises and difficulties. Hum. Immunol. 2008;69:165-73.
115. Terness P, Oelert T, Ehser S, et al. Mitomycin C-treated dendritic cells inactivate autoreactive T cells: toward the development of a tolerogenic vaccine in autoimmune diseases. Proc. Natl. Acad. Sci. U.S.A 2008;105:18442-7.
116. Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH. Induction of tolerance by IL-10-treated dendritic cells. J. Immunol. 1997; 4772-80. (Pubitemid 127471012)
117. Palomares O, Yaman G, Azkur AK, Akkoc T, Akdis M, Akdis CA. Role of Treg in immune regulation of allergic diseases. Eur. J. Immunol. 2010;40:1232-40.
118. Jutel M, Akdis M, Blaser K, Akdis CA. Mechanisms of allergen specific immunotherapy - T-cell tolerance and more. Allergy 2006;61:796-807. (Pubitemid 43893981)
119. Verhagen J, Taylor A, Blaser K, Akdis M, Akdis CA. T regulatory cells in allergen-specific immunotherapy. Int. Rev. Immunol. 2005;24:533-48.
120. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int. J. Cancer 2010;127:759-67.
121. Desar IM, Jacobs JF, Stillebroer AB, et al. Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients. Int. J. Cancer 2010 Sep 13. [Epub ahead of print].
122. Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 2004;34:336-44.
123. Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol.Immunother. 2007;56: 641-8. (Pubitemid 46348738)
124. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005; 105:4743-8.
125. Battaglia M, Stabilini A, Migliavacca B, Horejs-Hoeck J, Kaupper T, Roncarolo MG. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J. Immunol. 2006;177: 8338-47.
126. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest 2005;115:3623-33. (Pubitemid 43121851)
127. Agarwala SS. Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma. Melanoma Res. 2010;20:1-10.
128. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of antiCTLA-4 antibodies. J. Exp. Med. 2009;206:1717-25.
129. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol. 2002;3: 135-42.
130. Mitsui J, Nishikawa H, Muraoka D, et al. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clin. Cancer Res. 2010; 16:2781-91.
131. Schuler G, Steinman RM. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 1997;186: 1183-7. (Pubitemid 27469012)
132. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007;449:419-26.
133. Tuettenberg A, Becker C, Huter E, Knop J, Enk AH, Jonuleit H. Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage Il melanoma patients. Int. J. Cancer 2006;118:2617-27.
134. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptideor tumor lysate-pulsed dendritic cells [see comments]. Nat Med 1998;4:328-32. (Pubitemid 28144092)
135. Eubel J, Enk AH. Dendritic cell vaccination as a treatment modality for melanoma. Expert. Rev. Anticancer Ther. 2009;9: 1631-42.
136. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003;299:1033-6. (Pubitemid 36222922)
137. Pasare C, Medzhitov R. Toll-dependent control mechanisms of CD4 T cell activation. Immunity. 2004;21:733-41. (Pubitemid 39487894)
138. Pasare C, Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Adv. Exp. Med. Biol. 2005;560:11-8.
139. Liu HM, Newbrough SE, Bhatia SK, Dahle CE, Krieg AM, Weiner GJ. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor. Blood 1998;92: 3730-6. (Pubitemid 28525200)
140. Sutmuller RP, Morgan ME, Netea MG, Grauer O, Adema GJ. Toll-like receptors on regulatory T cells: expanding immune regulation. Trends Immunol. 2006;27:387-93. (Pubitemid 44038663)
141. Hodi FS, Butler M, Oble DA, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc. Natl. Acad. Sci. U.S.A 2008;105:3005-10.